Evidence summaries: new medicines

'Evidence summaries: new medicines' help commissioners, budget holders and groups such as Area Prescribing Committees make informed decisions and aid local planning on the introduction of key new medicines.

They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, considered to be of significance to the NHS. The medicines selected have recently been introduced in the UK, or may be introduced in the UK in the next 6-12 months.

The strengths and weaknesses of the relevant evidence are critically reviewed, and a value assessment of each medicine is made based on its safety, effectiveness, patient factors and resource implications, but the ‘Evidence summaries: new medicines' are not formal NICE guidance.

The NHS Constitution gives patients the right to expect that decisions about the funding of medicines and treatments will be made rationally following a proper consideration of the evidence. Where there is no guidance from NICE, these summaries help to ensure consistent access to evidence for decision-makers.

Our integrated process statement sets out how we select topics and prepare the summaries.

The National Prescribing Centre (NPC) legacy website has an archive of the NPC's new medicines rapid reviews.

Published Evidence summaries: new medicines

Title Date published
ESNM1 Clostridium difficile infection: fidaxomicin 13 July 2012
ESNM2 Idiopathic overactive bladder syndrome: botulinum toxin A 17 September 2012
ESNM3 Asthma: fluticasone/formoterol (Flutiform) combination inhaler 12 October 2012
ESNM4 Type 2 diabetes: insulin degludec 2 November 2012
ESNM5 Type 1 diabetes: insulin degludec 2 November 2012
ESNM6 Adalimumab for the treatment of moderately to severely active ulcerative colitis in adults 2 November 2012
ESNM7 Partial-onset seizures in epilepsy: perampanel as adjunctive treatment 14 December 2012
ESNM8 Chronic obstructive pulmonary disease: aclidinium bromide 7 January 2013
ESNM9 Chronic obstructive pulmonary disease: glycopyrronium bromide 7 January 2013
ESNM10 Type 2 diabetes: lixisenatide 18 January 2013
ESNM11 Acute diarrhoea in adults: racecadotril 12 March 2013
ESNM12 Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration 12 March 2013
ESNM13 Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab 12 March 2013
ESNM14 Actinic keratosis: ingenol mebutate gel 19 March 2013
ESNM15 Schizophrenia: lurasidone 9 April 2013
ESNM16 Irritable bowel syndrome with constipation in adults: linaclotide 9 April 2013
ESNM17 Partial-onset seizures in epilepsy: zonisamide as monotherapy 16 April 2013
ESNM18 Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil 19 April 2013
ESNM19 Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate 7 May 2013
ESNM20 Type 2 diabetes: alogliptin 21 May 2013
ESNM21 Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol 18 June 2013
ESNM22 Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment 25 June 2013
ESNM23 Gouty arthritis: canakinumab 23 July 2013
ESNM24 Type 1 diabetes: insulin degludec 10 September 2013
ESNM25 Type 2 diabetes: insulin degludec 10 September 2013
ESNM26 Type 2 diabetes: lixisenatide 24 September 2013
ESNM27 Secondary prevention in acute coronary syndrome: rivaroxaban 29 October 2013
ESNM28 Combined oral contraception: nomegestrol/estradiol (Zoely) 17 December 2013
ESNM29 Alcohol dependence: nalmefene 17 December 2013
ESNM30 Prostate cancer: triptorelin (Decapeptyl SR) 13 January 2014
ESNM31 Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) 28 January 2014
ESNM32 Relapsed and refractory multiple myeloma: pomalidomide 4 February 2014
ESNM33 Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) 11 February 2014
ESNM34 Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler 3 March 2014
ESNM35 Type 2 diabetes: empagliflozin 11 March 2014
ESNM36 Systemic juvenile idiopathic arthritis: canakinumab 18 March 2014
ESNM37 Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy 18 March 2014
ESNM38 Induction of labour: misoprostol vaginal delivery system 25 March 2014
ESNM39 Schizophrenia: aripiprazole prolonged-release suspension for injection 26 March 2014

Evidence summaries new medicines: coming soon

Title Expected date of
Dapoxetine: premature ejaculation May 2014
Levonorgestrel 13.5mg intrauterine system (Jaydess, Bayer) - Up to 3 years contraception June 2014
Certolizumab pegol: second/third line treatment of psoriatic arthritis June 2014
Brimonidine (Mirvaso, Galderma): Gel for facial erythema of rosacea July 2014
Telavancin (Vibativ, Clinigen)IV antibiotic for treatment of adults with nosocomial pneumonia caused by MRSA July 2014
Avanafil (Spedra, Menarini) Erectile dysfunction in adult men August 2014
Rituximab SC non Hodgkins lymphoma August 2014

This page was last updated: 28 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.